Option Care Health Reports Q2 2026 Earnings Call Highlights
In its second-quarter earnings call for fiscal year 2026, Option Care Health reported strong performance driven by high-single-digit organic growth in the acute care portfolio. The company attributed this success to its national scale and local responsiveness that support hospital discharge processes. Meanwhile, the chronic inflammatory disease (CID) portfolio showed signs of stabilization after a first-quarter reset, with patient numbers increasing despite biosimilar pricing challenges. Management highlighted robust performance from the IG neurology and rare/orphan portfolios due to strong pharmaceutical partnerships and clinical expertise in managing complex therapies. Operational improvements were driven by AI and analytics tools optimizing nursing routes and administrative tasks like claims processing. The company also expanded its ambulatory infusion clinic network with five new facilities, contributing to a 20% year-over-year increase in patient visits. For the full year of 2026, Option Care expects revenue headwinds from CID biosimilars but remains optimistic about sequential growth and EBITDA expansion. The company repurchased $150 million worth of shares during Q2 while maintaining a net debt leverage ratio of 2.1x.
Tickers: $OPCH
Topics: financial performance healthcare infusion services pharmaceuticals